Patents by Inventor Dominique Bourel

Dominique Bourel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 10081683
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: September 25, 2018
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Use of ADCC-optimized antibodies for treating low-responder patients
    Patent number: 9879089
    Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: January 30, 2018
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Dominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
  • MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION
    Publication number: 20180002442
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: June 7, 2017
    Publication date: January 4, 2018
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: ROLAND BELIARD, Dominique BOUREL, Arnaud GLACET, Christophe de ROMEUF, Nicolas BIHOREAU, Emmanuel NONY
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9718889
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: August 1, 2017
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Amaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9718890
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 1, 2017
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9708409
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 18, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS
    Publication number: 20150307624
    Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
    Type: Application
    Filed: May 1, 2015
    Publication date: October 29, 2015
    Applicant: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Dominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
  • MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION
    Publication number: 20150266972
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: April 1, 2015
    Publication date: September 24, 2015
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland BELIARD, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Use of ADCC-optimized antibodies for treating weak patients
    Patent number: 9109020
    Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: August 18, 2015
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Dominique Bourel, Sylvie Jorieux, Christophe De Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
  • MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION
    Publication number: 20150152189
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 4, 2015
    Applicant: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Amaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION
    Publication number: 20140162356
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: January 16, 2014
    Publication date: June 12, 2014
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 8685725
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: April 1, 2014
    Assignee: Labortoire Francais du Fractionnement et des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS
    Publication number: 20140017243
    Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 16, 2014
    Inventors: Dominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
  • Use of ADCC-optimized antibodies for treating weak patients
    Patent number: 8501171
    Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: August 6, 2013
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Dominique Bourel, Sylvie Jorieux, Christophe De Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 8409572
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 2, 2013
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Anti-D monoclonal antibodies
    Patent number: 8357370
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fc? receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: January 22, 2013
    Assignee: LFB Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION
    Publication number: 20120259095
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 11, 2012
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • ANTI-D MONOCLONAL ANTIBODIES
    Publication number: 20120258096
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fc? receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Application
    Filed: April 10, 2012
    Publication date: October 11, 2012
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Method for treating infectious disease using monoclonal antibodies
    Patent number: 8178093
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fc? receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: May 15, 2012
    Assignee: LFB Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Amaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Method for treating cancer using monoclonal antibodies
    Patent number: 8153124
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fc? receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: April 10, 2012
    Assignee: LFB Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Amaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony